AI-generated summary
In a streptozotocin-induced diabetic neuropathy mouse model, the authors report that photobiomodulation at 660 nm reduced pain-related responses in a way they associated with central opioid release. After 21 consecutive applications, they also report higher nerve growth factor levels, increased mitochondrial content and regulated Parkin in the sciatic nerve. The findings come from an animal study.
- Who or what was studied
- Mice with diabetic peripheral neuropathy induced by streptozotocin
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The study is in mice, and the abstract does not state a sample size or describe a control group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
- Energy density (fluence)
- 1.6 J/cm2
- Power
- 30 mW
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Neuropathy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.